Central Corneal Thickness and Glaucoma Treatment: An Italian Multicenter Cross-Sectional Study

Central corneal thickness (CCT) is an important parameter in the assessment of any potential glaucoma patient. While it affects prognosis in ocular hypertension, its value in patients diagnosed with glaucoma is less certain. There are several biological factors and genetic components that may influence glaucoma progression, which have been associated with thinner CCT. The CCT itself can be affected by several factors including ethnicity, age, sex, glaucoma medications, genetics, and the subtype of glaucoma. Besides, there is variability in the measurement of CCT between difference types of devices. These factors need to be considered in the evaluation of glaucoma patients' CCT and its effect on interpretation of intraocular pressure levels and risk stratification.

show abstract

“…In healthy corneas there was no effect on the endothelium [100]. In POAG, an increase [101] and no change [98] in CCT both have been reported.…”

Section: Topical Medicationsmentioning

confidence: 90%

“…An increase in CCT can also occur as reported in brimatoprost and latanoprost [97]. Iester et al showed no change to CCT in their Italian Glaucoma Register study [98]. No factor has been identified to explain the difference; however, many of those reporting a decrease have had more NTG patients.…”

Section: Topical Medicationsmentioning

confidence: 93%

The thick and thin of the central corneal thickness in glaucoma

Belovay

Goldberg

2018

Eye

View full text Add to dashboard Cite

show abstract

“… 18 , 19 These findings were consistent with those of De Paoli et al as an interim analysis of a phase II multicenter study presented at a European Society for Medical Oncology conference. 20 …”

Section: Discussionmentioning

confidence: 99%

Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction

Wang

Zhang

Qiao

et al. 2015

The American Journal of the Medical Sciences

View full text Add to dashboard Cite

Abstract:Objective:This study was conducted to investigate the efficacy and safety of using a concurrent neoadjuvant chemoradiotherapy (a XELOX regimen) to treat adenocarcinoma of the gastroesophageal junction.Methods:Seventy-six patients having resectable adenocarcinoma at the gastroesophageal junction (T3/4, N+, M0) were recruited to participate and randomly assigned to either a chemoradiotherapy group or a surgery group. Patients in the chemoradiotherapy group were orally given capecitabine (1,000 mg/m2, twice daily for 14 days, days 1–14) and intravenous oxaliplatin (130 mg/m2 on day 1) for 2 cycles. Radiotherapy was performed with a total of 45 Gy administered in 25 sessions for 5 weeks. Patients in the surgery group received only surgical intervention.Results:In the concurrent chemoradiotherapy group, the overall response rate was 55.6% (20/36), tumor control rate was 100% and a pathological complete response was achieved in 16.7% (6/36). The entire chemoradiotherapy group had R0 resections as did 80% of the surgery group (32/40) (P < 0.05). In the concurrent chemoradiotherapy group, 6 patients developed grade 3 side effects. Treatment was either discontinued or the dose adjusted. Major hematological side effects in the chemoradiotherapy group included leukopenia, neutropenia, anemia and thrombocytopenia. Nonhematological side effects included nausea, vomiting and appetite loss. Chemoradiotherapy-related death was not observed.Conclusions:Concurrent neoadjuvant chemoradiotherapy administration increased the rate of R0 resection and demonstrated favorable safety in patients with Siewert II or III adenocarcinoma at the gastroesophageal junction. These results support the use of neoadjunctive chemoradiotherapy in the treatment of adenocarcinoma of the gastroesophageal junction.

show abstract

“…Yet, we measured CCT using Pentacam, which is not the standard (even if there are reports suggesting that it correlates well with the gold standard, ie ultrasound pachimetry [ 27 , 28 ]). Further studies are needed to better understand the relationship between CCT and IOP measurements, in particular those obtained with ART, as it is complex and incompletely determined in both normal subjects and glaucoma patients [ 29 - 31 ].…”

Section: Discussionmentioning

confidence: 99%

Repeatability and reproducibility of applanation resonance tonometry: a cross-sectional study

et al. 2015

Self Cite

View full text Add to dashboard Cite

BackgroundTo assess repeatability (intra-observer variability) and reproducibility (inter-operator variability) of intraocular pressure (IOP) measurements with servo-controlled Bioresonator Applanation Resonance Tonometry (ART) and to evaluate possible influential factors.MethodsThe study included 178 patients (115 glaucoma and 63 controls; one eye per subject). IOP was measured once with a Goldmann applanation tonometer (GAT) and twice by ART (ART1, ART2), in randomized sequence, by a single operator to assess intra-operator variability. Each ART measurement consisted on 3 readings. To assess inter-operator variability 2 evaluators performed 2 measurements each (in random order) on the same patient. Repeatability and reproducibility were assessed by the coefficient of variation (CoV) and intraclass correlation coefficient (ICC).ResultsIn the entire cohort, ART1 was 0.4 ± 2.2 mmHg (−7.0 to 5.7 mmHg) higher than ART2 (p = 0.03) regardless of test order. Intra-operator CoV was 7.0% ± 6.3%, and ICC was 0.80-0.92. Inter-operator CoV ranged between 5.7% ± 6.1% and 8.2% ± 7.2%, and ICC between 0.86 and 0.97. ART1 and 2 were respectively 1.7 ± 3.1 and 1.3 ± 3.1 mmHg higher than GAT (p < 0.01). Test-retest difference with ART fell within ±1 mmHg in 41% of cases, within ±2 mmHg in 70%, within ±3 mmHg in 85%. 15% had a test-retest difference higher than ± 3 mmHg; Bland-Altman 95% intervals of confidence were −3.9 and +4.6 mmHg. Results were unaffected by age, diagnosis, central corneal thickness, keratometry, operator, randomization sequence.ConclusionsIn most cases ART repeatability and reproducibility were high, with no differences due to patients’ characteristics. ART measurements overestimated GAT by a mean of 1.3-1.7 mmHg.

show abstract

Central Corneal Thickness and Glaucoma Treatment: An Italian Multicenter Cross-Sectional Study

Abstract: No significant difference in CCT was found between patients treated with PGA and TCAI, suggesting that these topical medications did not statistically and clinically change the CCT.

Cited by 12 publications

References 31 publications

The thick and thin of the central corneal thickness in glaucoma

The thick and thin of the central corneal thickness in glaucoma

Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction

Repeatability and reproducibility of applanation resonance tonometry: a cross-sectional study

Contact Info

Product

Resources

About